The U.S. Food and Drug Administration announced the final guidance, Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development. The guidance provides a framework for considering neurodevelopmental evaluations that could be useful to assess long-term safety of a medical product intended for use in newborns, and replaces draft guidance issued in February 2023 with the same name.
Treating newborns with medical products coincides with a time of critical growth and development. Short-term safety evaluations typical for adults or other populations may fail to identify important adverse effects in newborns, which may follow early-life exposures. Long-term safety studies are often important to assess the safety of medical products used in newborns because important health effects resulting from medical products used during the newborn period may not become apparent until after a baby has grown older.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!